Stabilis

Pethidine hydrochloride



Noms commerciaux

Aldodan	Autriche, Iran, Turquie
Alodan	Autriche, Iran
Cluyer	Argentine
Demerol	Canada, Etats Unis d'Amérique, Vénézuela
Dolantin	Allemagne
Dolantina	Brésil, Espagne
Dolantine	Belgique, Luxembourg
Dolargan	Hongrie, Pologne
Dolcontral	Allemagne, Pologne
Dolosal	Tunisie
Meperidina	Argentine, Colombie
Meperidine	Canada, Etats Unis d'Amérique
Pethidin	Allemagne, Belgique
Pethidine	France, Grande Bretagne, Iran, Irlande, Islande, Malaisie, Nouvelle Zélande, Suisse
Petidin	Danemark, Finlande, Norvège, Suède
Petidina	Chili

Stabilité des solutions

PVC		2,5 mg/ml	25°C		24			1292
PVC		1,2 mg/ml	21°C		36			340
PP		0,25 & 30 mg/ml	22°C		28			1750
PP		0,25 & 30 mg/ml	4°C		28			1750
PP		10 mg/ml	-20°C		84			119
PP		10 mg/ml	23°C		84			119
PP		10 mg/ml	4°C		84			119
?		10 mg/ml	37°C	?	90			1735

Stabilité en mélange

		25 mg/ml	25°C	?	Chlorpromazine hydrochloride : 6,25 mg/ml Hydroxyzine dihydrochloride : 12,5 mg/ml	366	342
		5,5 mg/ml	25°C		Palonosetron hydrochloride : 25 µg/ml	4	2196
PVC		25 mg/ml	4°C		Chlorpromazine hydrochloride : 6,25 mg/ml Hydroxyzine dihydrochloride : 12,5 mg/ml	366	342
PVC		7.35 mg/ml	32°C	?	Metoclopramide hydrochloride : 0.15 mg/ml	48	930
PVC		4 mg/ml	22°C	?	Ondansetron hydrochloride : 0,1 & 1 mg/ml	31	332
PVC		8 mg/ml	25°C		Clonidine hydrochloride : 0,003 mg/ml	21	2184
PVC		4 mg/ml	32°C	?	Ondansetron hydrochloride : 0,1 & 1 mg/ml	7	332
PVC		4 mg/ml	4°C		Ondansetron hydrochloride : 0,1 & 1 mg/ml	31	332
PP		8,33 mg/ml	23°C		Ondansetron hydrochloride : 1,33 mg/ml	24	815
PP		8,33 mg/ml	4°C		Ondansetron hydrochloride : 1,33 mg/ml	24	815

Facteur influençant la stabilité

	NaHCO3			3525

Compatibilités

		Pethidine hydrochloride Aciclovir sodium		3595
		Pethidine hydrochloride : 1 mg/ml Aciclovir sodium : 5 mg/ml		336
		Pethidine hydrochloride : 10 mg/ml Aciclovir sodium : 5 mg/ml		62
		Pethidine hydrochloride : 100 mg/ml Aciclovir sodium : 5 mg/ml		132
		Pethidine hydrochloride : 4 mg/ml Allopurinol sodium : 3 mg/ml		307
		Pethidine hydrochloride : 4 mg/ml Amifostine : 10 mg/ml		3
		Pethidine hydrochloride : 10 mg/ml Amikacin sulfate : 5 mg/ml		405
		Pethidine hydrochloride : 100 mg/ml Amikacin sulfate : 50 mg/ml	0.45	132
		Pethidine hydrochloride Aminophylline		3525

		Pethidine hydrochloride Amobarbital sodium		3525
		Pethidine hydrochloride : 4 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Pethidine hydrochloride : 10 mg/ml Ampicillin sodium - sulbactam sodium : 30 mg/ml		406
		Pethidine hydrochloride : 10 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Pethidine hydrochloride : 10 mg/ml Atenolol : 0.5 mg/ml		62
		Pethidine hydrochloride : 4 mg/ml Aztreonam : 40 mg/ml		99
		Pethidine hydrochloride : 10 mg/ml Aztreonam : 20 mg/ml		62
		Pethidine hydrochloride : 10 mg/ml Bivalirudin : 5 mg/ml		1713
		Pethidine hydrochloride : 10 mg/ml Bumetanide : 0.25 mg/ml		62
		Pethidine hydrochloride : 10 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Pethidine hydrochloride : 10 mg/ml Cefalotin sodium : 20 mg/ml		405
		Pethidine hydrochloride : 10 mg/ml Cefamandole nafate : 20 mg/ml		405
		Pethidine hydrochloride : 10 mg/ml Cefamandole nafate : 40 mg/ml		406
		Pethidine hydrochloride : 0,5 mg/ml Cefazolin sodium : 10 mg/ml		111
		Pethidine hydrochloride : 10 mg/ml Cefmetazole sodium : 100 mg/ml		93
		Pethidine hydrochloride : 10 mg/ml Cefoperazone sodium : 20 mg/ml		405
		Pethidine hydrochloride : 10 mg/ml Cefoperazone sodium : 20 mg/ml		405
		Pethidine hydrochloride : 10 mg/ml Ceforanide : 20 mg/ml		405
		Pethidine hydrochloride : 10 mg/ml Cefotaxime sodium : 20 mg/ml		405
		Pethidine hydrochloride : 10 mg/ml Cefoxitin sodium : 20 mg/ml		405
		Pethidine hydrochloride : 10 mg/ml Cefoxitin sodium : 40 mg/ml		406
		Pethidine hydrochloride : 10 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Pethidine hydrochloride : 10 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Pethidine hydrochloride : 10 mg/ml Ceftazidime : 20 & 40 mg/ml		62
		Pethidine hydrochloride : 10 mg/ml Ceftizoxime sodium : 20 mg/ml		405
		Pethidine hydrochloride : 10 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269

		Pethidine hydrochloride : 4 mg/ml		301
		Pethidine hydrochloride : 10 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Pethidine hydrochloride Ceftobiprole medocaril sodium		4650
		Pethidine hydrochloride : 50 mg/ml		939
		Pethidine hydrochloride : 4 mg/ml Cladribine : 0.015 mg/ml		1496
		Pethidine hydrochloride : 10 mg/ml		62
		Pethidine hydrochloride : 10 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Pethidine hydrochloride : 10 mg/ml Ceftriaxone disodium : 20 & 40 mg/ml		62
		Pethidine hydrochloride : 10 mg/ml Cefuroxime sodium : 30 mg/ml		405
		Pethidine hydrochloride : 10 mg/ml Chloramphenicol sodium succinate : 20 mg/ml		405
		Pethidine hydrochloride : 4 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Pethidine hydrochloride : 4 mg/ml Cladribine : 0.5 mg/ml		1496
		Pethidine hydrochloride : 10 mg/ml Clindamycin phosphate : 12 mg/ml		405
		Pethidine hydrochloride : 8 mg/ml Clonidine hydrochloride : 0.003 mg/ml		2184
		Pethidine hydrochloride : 10 mg/ml Co-trimoxazole : 4/0.8 mg/ml		405
		Pethidine hydrochloride : 10 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Pethidine hydrochloride : 10 mg/ml Digoxin : 250 µg/ml		62
		Pethidine hydrochloride : 100 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
		Pethidine hydrochloride : 10 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Pethidine hydrochloride : 10 mg/ml Diphenhydramine hydrochloride : 1&50 mg/ml		62
		Pethidine hydrochloride : 100 mg/ml Dobutamine hydrochloride : 2 mg/ml		1041
		Pethidine hydrochloride : 10 mg/ml Dobutamine hydrochloride : 1 mg/ml		62
		Pethidine hydrochloride : 4 mg/ml Docetaxel : 0.9 mg/ml		1754
		Pethidine hydrochloride : 10 mg/ml Dopamine hydrochloride : 1.6 mg/ml		62
		Pethidine hydrochloride : 10 mg/ml Doripenem : 5 mg/ml		2262
		Pethidine hydrochloride : 4 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Pethidine hydrochloride : 4 mg/ml		1415

		Pethidine hydrochloride : 10 mg/ml Dexamethasone sodium phosphate : 0.2 mg/ml		62
		Pethidine hydrochloride : 10 mg/ml Doxycycline hyclate : 1 mg/ml		405
		Pethidine hydrochloride : 10 mg/ml Droperidol : 2.5 mg/ml		62
		Pethidine hydrochloride Eptifibatide		3934
		Pethidine hydrochloride : 10 mg/ml Erythromycin lactobionate : 5 mg/ml		405
		Pethidine hydrochloride : 4 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Pethidine hydrochloride : 4 mg/ml Famotidine : 2 mg/ml		215
		Pethidine hydrochloride : 10 mg/ml Famotidine : 0.2 mg/ml		62
		Pethidine hydrochloride : 4 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Pethidine hydrochloride : 4 mg/ml Filgrastim : 30 µg/ml		244
		Pethidine hydrochloride : 5 mg/ml Flucloxacillin sodium : 20 mg/ml		1232
		Pethidine hydrochloride : 10 mg/ml Fluconazole : 1 mg/ml		62
		Pethidine hydrochloride : 4 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Pethidine hydrochloride : 10 mg/ml Fosfomycin : 30 mg/ml		4055
		Pethidine hydrochloride : 5 mg/ml Furosemide : 1 mg/ml		1232
		Pethidine hydrochloride : 10 mg/ml Furosemide : 10 mg/ml		62
		Pethidine hydrochloride Glycopyrronium bromide		3599
		Pethidine hydrochloride : 0.1 mg/ml		340
		Pethidine hydrochloride : 10 mg/ml Furosemide : 0.8 mg/ml		62
		Pethidine hydrochloride : 10 mg/ml Furosemide : 2.4 mg/ml		62
		Pethidine hydrochloride : 50 mg/ml Gallium nitrate : 1 mg/ml		91
		Pethidine hydrochloride : 4 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Pethidine hydrochloride : 10 mg/ml Gentamicin sulfate : 0.8 mg/ml		405
		Pethidine hydrochloride : 4 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Pethidine hydrochloride Heparin sodium		3525
		Pethidine hydrochloride : 10 mg/ml Heparin sodium : 60 UI/ml		406

		Pethidine hydrochloride Heparin sodium		3540
		Pethidine hydrochloride : 4 mg/ml Hetastarch : 60 mg/ml		1721
		Pethidine hydrochloride : 10 mg/ml Hydrocortisone sodium succinate : 2 mg/ml		62
		Pethidine hydrochloride : 1 & 50 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Pethidine hydrochloride : 10 mg/ml Imipenem - cilastatin sodium : 5 mg/ml		62
		Pethidine hydrochloride : 50 mg/ml Insulin : 0.2 UI/ml		129
		Pethidine hydrochloride : 10 mg/ml Insulin : 0.2 UI/ml		406
		Pethidine hydrochloride : 10 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Pethidine hydrochloride : 10 mg/ml Kanamycin sulfate : 2.5 mg/ml		405
		Pethidine hydrochloride : 12 mg/ml Ketamine hydrochloride : 2 mg/ml		321
		Pethidine hydrochloride : 100 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Pethidine hydrochloride Ketorolac tromethamine		3593
		Pethidine hydrochloride : 10 mg/ml Labetalol hydrochloride : 5 mg/ml		62
		Pethidine hydrochloride : 10 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Pethidine hydrochloride : 10 mg/ml Lidocaine hydrochloride : 1 mg/ml		62
		Pethidine hydrochloride : 4 mg/ml Linezolid : 2 mg/ml		1925
		Pethidine hydrochloride : 10 mg/ml Magnesium sulfate : 16,67 >> 100 mg/ml		517
		Pethidine hydrochloride : 4 mg/ml Melphalan : 0.1 mg/ml		169
		Pethidine hydrochloride : 10 mg/ml Methylprednisolone sodium succinate : 2.5 mg/ml		62
		Pethidine hydrochloride : 16.67 mg/ml Metoclopramide hydrochloride : 6.67 mg/ml		930
		Pethidine hydrochloride : 7.35 mg/ml Metoclopramide hydrochloride : 0.15 mg/ml		930
		Pethidine hydrochloride : 10 mg/ml Metoclopramide hydrochloride : 0.2 mg/ml		62
		Pethidine hydrochloride : 10 mg/ml Metoprolol tartrate : 1 mg/ml		62
		Pethidine hydrochloride : 10 mg/ml Metronidazole : 5 mg/ml		405
		Pethidine hydrochloride : 10 mg/ml Micafungin : 1.5 mg/ml		2108
		Pethidine hydrochloride : 50 mg/ml Midazolam hydrochloride : 2.5 mg/ml		404

		Pethidine hydrochloride : 10 mg/ml Minocycline hydrochloride : 0.2 mg/ml	◆	405
		Pethidine hydrochloride Morphine sulfate		3525
		Pethidine hydrochloride Morphine sulfate		3531
		Pethidine hydrochloride : 10 mg/ml Moxalactam : 20 mg/ml	◆	405
		Pethidine hydrochloride : 10 mg/ml Nafcillin sodium : 20 mg/ml	◆	405
		Pethidine hydrochloride : 10 mg/ml Nafcillin sodium : 20 & 30 mg/ml	▲	406
		Pethidine hydrochloride : 4 mg/ml Ondansetron hydrochloride : 1 mg/ml	▲	334
		Pethidine hydrochloride : 4 mg/ml Ondansetron hydrochloride : 0.1 & 1 mg/ml	▲	332
		Pethidine hydrochloride : 8.33 mg/ml Ondansetron hydrochloride : 1.33 mg/ml	▲	815
		Pethidine hydrochloride : 10 mg/ml Oxacillin sodium : 20 mg/ml	◆	405
		Pethidine hydrochloride : 10 mg/ml Oxaliplatin : 0,5 mg/ml	◆	1662
		Pethidine hydrochloride : 10 mg/ml Oxytocin : 12 UI/ml	▲	406
		Pethidine hydrochloride : 4 mg/ml Paclitaxel : 1.2 mg/ml	◆	248
		Pethidine hydrochloride : 10 mg/ml Palonosetron hydrochloride : 50 µg/ml	◆	2196
15'		Pethidine hydrochloride Pantoprazole sodium		2090
		Pethidine hydrochloride : 50 mg/ml Paracetamol : 10 mg/ml	◆	4435
		Pethidine hydrochloride : 50 mg/ml Paracetamol : 10 mg/ml	∅	3571
		Pethidine hydrochloride Parecoxib sodium		3504
		Pethidine hydrochloride : 10 mg/ml Pemetrexed disodium : 20 mg/ml	▲	1953
		Pethidine hydrochloride : 10 mg/ml Penicillin G potassium : 0.1 MUI/ml	◆	405
		Pethidine hydrochloride Pentobarbital sodium		3525
		Pethidine hydrochloride Phenobarbital sodium		3525
		Pethidine hydrochloride Phenytoin sodium		3525
		Pethidine hydrochloride : 10 mg/ml Piperacillin sodium : 60 mg/ml	◆	405
		Pethidine hydrochloride : 4 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml	◆	81
		Pethidine hydrochloride : 10 mg/ml Plazomicin sulfate : 24 mg/ml	▲	4145

		Pethidine hydrochloride : 10 mg/ml Potassium chloride : 400 mEq/l		62
		Pethidine hydrochloride : 4 mg/ml Propofol : 10 mg/ml		300
		Pethidine hydrochloride : 10 mg/ml Propranolol hydrochloride : 1 mg/ml		62
		Pethidine hydrochloride : 10 mg/ml Ranitidine hydrochloride : 0.5 mg/ml		406
		Pethidine hydrochloride : 100 mg/ml Ranitidine hydrochloride : 25 mg/ml		58
		Pethidine hydrochloride : 10 mg/ml Ranitidine hydrochloride : 1.2 & 2 mg/ml		406
		Pethidine hydrochloride : 4 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Pethidine hydrochloride : 4 mg/ml Sargramostim : 10 µg/ml		335
		Pethidine hydrochloride Sodium bicarbonate		3525
		Pethidine hydrochloride : 50 mg/ml Sugammadex : 100 mg/ml		3372
		Pethidine hydrochloride : 10 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Pethidine hydrochloride : 4 mg/ml Teniposide : 0.1 mg/ml		905
		Pethidine hydrochloride Thiopental sodium		3525
		Pethidine hydrochloride Thiopental sodium		3675
		Pethidine hydrochloride : 4 mg/ml Thiotepa : 1 mg/ml		249
		Pethidine hydrochloride : 10 mg/ml Ticarcillin / clavulanic acid : 31 mg/ml		406
		Pethidine hydrochloride : 10 mg/ml Tobramycin sulfate : 0.8 mg/ml		405
		Pethidine hydrochloride : 10 mg/ml Tobramycin sulfate : 1.6 >> 2.4 mg/ml		406
		Pethidine hydrochloride : 10 mg/ml Vancomycin hydrochloride : 5 mg/ml		405
		Pethidine hydrochloride : 0.15 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Pethidine hydrochloride : 10 mg/ml Verapamil hydrochloride : 2.5 mg/ml		62
		Pethidine hydrochloride : 4 mg/ml Vinorelbine tartrate : 1 mg/ml		84

Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
58	Revue	Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	Revue	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
93	Revue	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
111	Revue	Lee DKT, Wong CY, Wang DP. Stability of cefazolin sodium and meperidine hydrochloride. Am J Health-Syst Pharm 1996 ; 53: 1608,1610.
119	Revue	Strong ML, Schaaf LJ, Pankaskie MC, Robinson DH. Shelf-lives and factors affecting the stability of morphine sulphate and meperidine (pethidine) hydrochloride in plastic syringes for use in patient-controlled analgesic devices. J Clin Pharm Ther 1994 ; 19: 361-369.
129	Revue	Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991 ; 48: 125-126.
132	Revue	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.

169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
321	Revue	Ambados F. Compatibility of ketamine hydrochloride and meperidine hydrochloride. Am J Health-Syst Pharm 1997 ; 54: 205.
332	Revue	Xu QA, Trissel LA, Fox JL. Compatibility of ondansetron hydrochloride with meperidine hydrochloride for combined administration. Ann Pharmacotherapy 1995 ; 29: 1106-1109.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.

336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
340	Revue	Macias JM, Martin WJ, Lloyd CW. Stability of morphine sulfate and meperidine hydrochloride in a parenteral nutrient formulation. Am J Hosp Pharm 1985 ; 42: 1087-1094.
342	Revue	Conklin CA, Kerege JF, Christensen JM. Stability of an analgesic-sedative combination in glass and plastic single-dose syringes. Am J Hosp Pharm 1985 ; 42: 339-342.
404	Revue	Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299.
405	Revue	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
406	Revue	Smythe MA, Patel MA, Gasloli RA. Visual compatibility of narcotic analgesics with selected intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 819-820.
491	Revue	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
517	Revue	Letourneau M. Visual compatibility of magnesium sulfate with narcotic analgesics. Am J Hosp Pharm 1992 ; 49: 838-839.
815	Revue	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
930	Revue	Hor MMS, Chan SY, Yow KL, Lim LY, Chan E. Stability of admixtures of pethidine and metoclopramide in aqueous solution, 5% dextrose and 0.9% sodium chloride. J Clin Pharm Ther 1997 ; 22: 339-345.
939	Revue	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
1041	Revue	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.

1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1292	Revue	Grassby PF, Roberts DE. Stability of epidural opiate solutions in 0.9 per cent sodium chloride infusion bags. Int J Pharm Pract 1995 ; 3: 174-177.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1735	Revue	Harvey SC, Toussaint CP, Coe SE, Watson EE, O?Neil MG, Patrick KS. Stability of mepiridine in an implantable infusion pump using capillary gas chromatography-mass spectrometry and a deuterated internal standard. J Pharm Biomed Anal 1999 ; 21: 577-583.
1750	Revue	Donelly RF, Bushfield TL. Chemical stability of meperidine hydrochloride in polypropylene syringes. Int J Pharm Compound 1998 ; 2: 463-465.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.

1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2184	Revue	Vranken JH, van Kan HJM, ven der Vegt MH. Stability and compatibility of a meperidine-clonidine mixture in portable pump reservoirs for the management of cancer pain syndromes. J Pain Symptom Manage 2006 ; 32, 4: 297-299.
2196	Revue	Trissel LA, Trusley C, Ben M, Kupiec TC. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration. Am J Health-Syst Pharm 2007 ; 64, 11: 1209-1213.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3372	Revue	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3504	Laboratoire	Parecoxib (Dynastat®) - Summary of Product Characteristics Pfizer 2012
3525	Laboratoire	Pethidine hydrochloride - Summary of product Characteristics AMCO Amdipharm Mercury 2012
3531	Laboratoire	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3540	Laboratoire	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3571	Revue	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3593	Laboratoire	Ketorolac trometamol (Ketorolac®) - Summary of Product Characteristics Beacon Pharmaceuticals 2011
3595	Laboratoire	Aciclovir - Summary of Product Characteristics Hospira 2009
3599	Laboratoire	Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics Amco Amdipharm Mercry 2013

3675	Laboratoire	Thiopental sodium - Summary of Product Characteristics Archimedes Pharma UK Ltd 2015
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3934	Laboratoire	Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4435	Revue	Hanifah S, Nugroho B.H, Chabib L. Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection. Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27.
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021

Dictionnaire

	Antalgique		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie	PVC	Polyvinyl chlorure
	Chlorure de sodium 0,9%		Lumière
	Jour		Glucose 5%
	Heure		Seringue polypropylène
	NaCl 0,9% ou glucose 5%		A l'abri de la lumière
?	Non précisé	?	Non précisée
	Stabilité en mélange		Solvant
	Molécule		Verre
	Eau pour préparation injectable	Ø	Aucun
PP	Polypropylène		Facteur influençant la stabilité
	Provoque		Dégradation
	Compatibilités		Incompatibilité non précisée
	Incompatible		Compatible
	Précipitation en 1 heure		Précipitation immédiate
0.45	Chlorure de sodium 0,45%		Turbidité immédiate
RL	Ringer lactate		Nutrition parentérale (mélange binaire)
	NaCl 0,9% + bactériosatique		Perte de turbidité
	Nutrition parentérale (mélange ternaire)		Turbidité à 24 heures
	Solvant spécifique		Changement de couleur
	Changement de couleur après 2 heures		Changement de couleur après 1 heure
	Précipitation en 15 minutes		Voie d'administration
	Intraveineuse		Perfusion intraveineuse
	Perfusion continue		Intramusculaire
	Sous cutanée		Intrathécale

	Bibliographie		Dictionnaire